- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Alfuzosin is a drug used to treat benign prostatic hyperplasia (BPH), a condition that affects the prostate gland in men. It is an alpha-blocker, meaning it works by relaxing the muscles in the prostate and bladder neck, allowing urine to flow more freely. It is also used to treat symptoms of an enlarged prostate, such as difficulty urinating, weak stream, and frequent urination. In the context of oncology drugs, Alfuzosin is used to treat urinary retention caused by prostate cancer. It is also used to reduce the risk of urinary retention in patients with prostate cancer who are undergoing radiation therapy.
Alfuzosin is available in both generic and brand-name formulations. Some of the companies that produce Alfuzosin include Mylan, Teva Pharmaceuticals, and Sandoz. Show Less Read more